Successful use of fenfluramine as an add‐on treatment for Dravet syndrome
Open accessAbstract
Summary: Purpose: Despite the development of new antiepileptic drugs, Dravet syndrome frequently remains therapy resistant and is a catastrophic epilepsy syndrome. Fenfluramine is an amphetamine‐like drug that has been used in the past as a part of antiobesity treatments. Because of the possible cardiac adverse effects (valve thickening, pulmonary hypertension) associated with use of fenfluramine, it was withdrawn from the market in 2001. In Belgium, a Royal Decree permitted examination of the potential anticonvulsive effects of fenfluramine in a clinical trial consisting of a small group of patients diagnosed with Dravet syndrome. Methods: Herein, we report 12 patients, 7 female and 5 male, with a genetically proven (11 of 12) diagnosis of Dravet syndrome who received fenfluramine as add‐on therapy. Key Findings: Their ages at their last evaluation ranged from 3–35 years. The mean dosage of fenfluramine was 0.34 (0.12–0.90) mg/kg/day. Exposure duration to fenfluramine ranged from 1–19 years. Seven of the patients who were still receiving the fenfluramine treatment at the time of the last visit had been seizure‐free for at least 1 year. In total, patients had been seizure‐free for a mean of 6 (1–19) years. In seven patients, the fenfluramine treatment was interrupted once during the follow‐up; seizures reappeared in three of the seizure‐free patients. Subsequent reintroduction of fenfluramine controlled the seizures in these three patients again. Only two patients exhibited a mild thickening of one or two cardiac valves without clinical significance. Significance: Compared with a recent long‐term follow‐up series in which a maximum of 16% of patients with Dravet syndrome were seizure‐free, our result of 70% of patients with Dravet syndrome remaining seizure‐free is noteworthy. Given the limitations of this observational study, a larger prospective study should be undertaken to confirm these promising results.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Identification of the efficacy of fenfluramine in Dravet syndrome followed the observation that it was particularly beneficial in children with drug-resistant, self-induced photosensitive epilepsy, resulting in seizure freedom in 7 of 12 patients with Dravet syndrome in one study.
“Identification of the efficacy of fenfluramine in Dravet syndrome followed the observation that it was particularly beneficial in children with drug-resistant, self-induced photosensitive epilepsy 195 , resulting in seizure freedom in 7 of 12 patients with Dravet syndrome in one study 196 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [196]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic Seizures
(1981) · Epilepsia · doi:10.1111/j.1528-1157.1981.tb06159.x · Cited by 3,433 · see citing works
De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy
Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., & De Jonghe, P. (2001) · The American Journal of Human Genetics · doi:10.1086/320609 · Cited by 1,292 · see citing works
Self-citationEpileptic Syndromes in Infancy, Childhood and Adolescence
Stephenson, J. B. P. (2004) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2004.03.001 · Cited by 685 · see citing works
The core Dravet syndrome phenotype
Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02994.x · Cited by 630 · see citing works
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568 · see citing works
The spectrum of SCN1A-related infantile epileptic encephalopathies
Harkin, L. A., McMahon, J. M., Iona, X., Dibbens, L. M., Pelekanos, J. T., Zuberi, S. M., Sadleir, L. G., Andermann, E., Gill, D. S., Farrell, K., et al. (2007) · Brain · doi:10.1093/brain/awm002 · Cited by 530 · see citing works
The genetics of Dravet syndrome
Marini, C., Scheffer, I. E., Nabbout, R., Suls, A., Jonghe, P. D., Zara, F., & Guerrini, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02997.x · Cited by 274 · see citing works
Dravet syndrome: The long‐term outcome
Genton, P., Velizarova, R., & Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03001.x · Cited by 266 · see citing works
LES EPILEPSIES GRAVES DE L'ENFANT.
Dravet, C. (1978) · Cited by 240 · see citing works
A long‐term follow‐up study of Dravet syndrome up to adulthood
Akiyama, M., Kobayashi, K., Yoshinaga, H., & Ohtsuka, Y. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02466.x · Cited by 192 · see citing works
SCN1A duplications and deletions detected in Dravet syndrome: Implications for molecular diagnosis
Marini, C., Scheffer, I. E., Nabbout, R., Mei, D., Cox, K., Dibbens, L. M., McMahon, J. M., Iona, X., Sánchez-Carpintero, R., Elia, M., et al. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02013.x · Cited by 173 · see citing works
Jobe, P. C., & Browning, R. A. (2005) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2005.07.014 · Cited by 163 · see citing works
Severe myoclonic epilepsy of infancy (Dravet syndrome): Recognition and diagnosis in adults
Jansen, F. E., Sadleir, L. G., Harkin, L. A., Vadlamudi, L., McMahon, J. M., Mulley, J. C., Scheffer, I. E., & Berkovic, S. F. (2006) · Neurology · doi:10.1212/01.wnl.0000249312.73155.7d · Cited by 157 · see citing works
The pharmacologic treatment of Dravet syndrome
Chiron, C., & Dulac, O. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03007.x · Cited by 151 · see citing works
Oguni, H., Hayashi, K., Awaya, Y., Fukuyama, Y., & Ōsawa, M. (2001) · Brain and Development · doi:10.1016/s0387-7604(01)00276-5 · Cited by 151 · see citing works
Protocadherin 19 mutations in girls with infantile-onset epilepsy
Marini, C., Mei, D., Parmeggiani, L., Norci, V., Calado, E., Ferrari, A. R., Moreira, A., Pisano, T., Specchio, N., Vigevano, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ed9e67 · Cited by 134 · see citing works
Epidemiology of Severe Myoclonic Epilepsy of Infancy
Hurst, D. L. (1990) · Epilepsia · doi:10.1111/j.1528-1157.1990.tb05494.x · Cited by 124 · see citing works
Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial
Coppola, G., Capovilla, G., Montagnini, A., Romeo, A., Spano, M. C., Tortorella, G., Veggiotti, P., Viri, M., & Pascotto, A. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(02)00010-4 · Cited by 119 · see citing works
An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy
Striano, P., Coppola, A., Pezzella, M., Ciampa, C., Specchio, N., Ragona, F., Mancardi, M. M., Gennaro, E., Beccaria, F., Capovilla, G., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000265222.24102.db · Cited by 115 · see citing works
Microdeletions involving theSCN1A gene may be common inSCN1A-mutation-negative SMEI patients
Suls, A., Claeys, K. G., Goossens, D., Harding, B., van Luijk, R., Scheers, S., Deprez, L., Audenaert, D., Dyck, T. V., Beeckmans, S., et al. (2006) · Human Mutation · doi:10.1002/humu.20350 · Cited by 114 · see citing works
Self-citationStiripentol open study in Japanese patients with Dravet syndrome
Inoue, Y., Ohtsuka, Y., Oguni, H., Tohyama, J., Baba, H., Fukushima, K., Ohtani, H., Takahashi, Y., & Ikeda, S. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02179.x · Cited by 113 · see citing works
Nonpharmacologic treatments of Dravet syndrome: Focus on the ketogenic diet
Caraballo, R. H. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03009.x · Cited by 99 · see citing works
Early diagnosis of severe myoclonic epilepsy in infancy
Yakoub, M., Dulac, O., Jambaqué, I., Chiron, C., & Plouin, P. (1992) · Brain and Development · doi:10.1016/s0387-7604(12)80147-1 · Cited by 99 · see citing works
McCann, U. D. (1997) · JAMA · doi:10.1001/jama.278.8.666 · Cited by 91 · see citing works
Topiramate in the treatment of severe myoclonic epilepsy in infancy
Nieto-Barrera, M., Candau, R. B., Nieto-Jiménez, M., Correa, A., & del Portal, L. R. (2000) · Seizure · doi:10.1053/seiz.2000.0466 · Cited by 89 · see citing works
Thanh, T. N., Chiron, C., Dellatolas, G., Rey, E., Pons, G., Vincent, J., & Dulac, O. (2002) · Archives de Pédiatrie · doi:10.1016/s0929-693x(02)00090-8 · Cited by 84 · see citing works
Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later
Dravet, C., Bureau, M., Bernardina, B. D., & Guerrini, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02993.x · Cited by 78 · see citing works
Topiramate in the Treatment of Highly Refractory Patients with Dravet Syndrome
Kröll‐Seger, J., Portilla, P., Dulac, O., & Chiron, C. (2006) · Neuropediatrics · doi:10.1055/s-2007-964867 · Cited by 74 · see citing works
Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy
Iannetti, P., Parisi, P., Spalice, A., Ruggieri, M., & Zara, F. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.02.014 · Cited by 74 · see citing works
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals
Dahl, C. F., Allen, M. R., Urie, P. M., & Hopkins, P. N. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-34 · Cited by 73 · see citing works
McCann, U. D. (1997) · JAMA · doi:10.1001/jama.1997.03550080076043 · Cited by 72 · see citing works
Clinical course of young patients with Dravet syndrome after vagal nerve stimulation
Zamponi, N., Passamonti, C., Cappanera, S., & Petrelli, C. (2010) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2010.09.003 · Cited by 68 · see citing works
Severe Myoclonic Epilepsy in Infancy: Toward an Optimal Treatment
Ceulemans, B., Boel, M., Claes, L. R. F., Dom, L., Willekens, H., Thiry, P., & Lagae, L. G. (2004) · Journal of Child Neurology · doi:10.1177/08830738040190070701 · Cited by 59 · see citing works
Self-citationAdd-On Therapy of Fenfluramine in Intractable Self-Induced Epilepsy
Boel, M., & Casaer, P. (1996) · Neuropediatrics · doi:10.1055/s-2007-973781 · Cited by 52 · see citing works
Self-citationFenfluramine Disrupts the Mitral Valve Interstitial Cell Response to Serotonin
Connolly, J. M., Bakay, M. A., Fulmer, J. T., Gorman, R. C., Gorman, J. H., Oyama, M. A., & Levy, R. J. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081101 · Cited by 52 · see citing works
Blastocystis hominisin Kathmandu, Nepal
Aicardi, J. F., & Gastaut, H. (1985) · New England Journal of Medicine · doi:10.1056/nejm198511283132218 · Cited by 52 · see citing works
Overall management of patients with Dravet syndrome
Ceulemans, B. (2011) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2011.03968.x · Cited by 51 · see citing works
Self-citationCoping With a Child With Dravet Syndrome: Insights From Families
Nolan, K., Camfield, C., & CAMFIELD, P. R. (2007) · Journal of Child Neurology · doi:10.1177/0883073808314162 · Cited by 50 · see citing works
Treatment of Self-Induced Photosensitive Epilepsy with Fenfluramine
(1985) · New England Journal of Medicine · doi:10.1056/nejm198511283132219 · Cited by 43 · see citing works
Dravet syndrome and deep brain stimulation: Seizure control after 10 years of treatment
Andrade, D. M., Hamani, C., Lozano, A. M., & Wennberg, R. A. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02408.x · Cited by 41 · see citing works
Riva, D., Vago, C., Pantaleoni, C., Bulgheroni, S., Mantegazza, M., & Franceschetti, S. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33029 · Cited by 40 · see citing works
Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels
Bělohlávková, S., Šimák, J., Kokešová, A., Hniličková, O., & Hampl, V. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.91.2.755 · Cited by 36 · see citing works
Fenfluramine Blocks Low‐Mg2+‐Induced Epileptiform Activity in Rat Entorhinal Cortex
Gentsch, K., Heinemann, U., Schmitz, B., & Behr, J. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00273.x · Cited by 28 · see citing works
Casaer, P., & Boel, M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.casa432.x · Cited by 27 · see citing works
Self-citationDopamine agonist treatment of self-induced pattern-sensitive epilepsy. a case report
Clemens, B. (1988) · Epilepsy Research · doi:10.1016/0920-1211(88)90044-7 · Cited by 27 · see citing works
Aicardi, J. F. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520320125029 · Cited by 26 · see citing works
Epilepsy in Children in Navarre, Spain: Epileptic Seizure Types and Epileptic Syndromes
Durá-Travé, T., Yoldi-Petri, M. E., & Gallinas-Victoriano, F. (2007) · Journal of Child Neurology · doi:10.1177/0883073807304207 · Cited by 26 · see citing works
Gastaut, H., Zifkin, B. G., & Rufo, M. (1987) · Journal of Autism and Developmental Disorders · doi:10.1007/bf01487068 · Cited by 23 · see citing works
Long‐Term Course of Childhood Epilepsy with Intractable Grand Mal Seizures
Fujiwara, T., Watanabe, M., Takahashi, Y., Higashi, T., Yagi, K., & Seino, M. (1992) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1992.tb00862.x · Cited by 21 · see citing works
Fenfluramine–Phentermine (Fen-Phen) and Seizures: Evidence for an Association
Spencer, D. C., Hwang, J., & Morrell, M. J. (2000) · Epilepsy & Behavior · doi:10.1006/ebeh.2000.0132 · Cited by 4 · see citing works
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 582 · see citing works
Symonds, J. D., Zuberi, S. M., Stewart, K., McLellan, A., O‘Regan, M., MacLeod, S., Jollands, A., Joss, S., Kirkpatrick, M., Brunklaus, A., et al. (2019) · Brain · doi:10.1093/brain/awz195 · Cited by 459 · see citing works
Lagae, L., Sullivan, J., Knupp, K., Laux, L., Polster, T., Nikanorova, M., Devinsky, O., Cross, J. H., Guerrini, R., Talwar, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32500-0 · Cited by 384 · see citing works
Self-citationThe Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell’Isola, G. B., Cara, G. D., Striano, P., & Verrottı, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.674483 · Cited by 276 · see citing works
Nabbout, R., Mistry, A., Zuberi, S., Villeneuve, N., Gil-Nagel, A., Sanchez-Carpintero, R., Stephani, U., Laux, L., Wirrell, E., Knupp, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4113 · Cited by 251 · see citing works
Pharmacology of cannabinoids in the treatment of epilepsy
Gaston, T. E., & Friedman, D. J. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.016 · Cited by 209 · see citing works
Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196 · see citing works
Drug development for refractory epilepsy: The past 25 years and beyond
Golyala, A., & Kwan, P. (2016) · Seizure · doi:10.1016/j.seizure.2016.11.022 · Cited by 188 · see citing works
Scheffer, I. E., & Liao, J. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2019.12.023 · Cited by 180 · see citing works
Zebrafish Models of Neurodevelopmental Disorders: Past, Present, and Future
Sakai, C., Ijaz, S., & Hoffman, E. J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00294 · Cited by 164 · see citing works
Balestrini, S., & Sisodiya, S. M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.014 · Cited by 158 · see citing works
Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome
Dinday, M. T., & Baraban, S. C. (2015) · eNeuro · doi:10.1523/eneuro.0068-15.2015 · Cited by 150 · see citing works
Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish
Sourbron, J., Smolders, I. J., de Witte, P. A. M., & Lagae, L. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00191 · Cited by 139 · see citing works
Self-citationDevelopmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 128 · see citing works
Fine, A. L., & Wirrell, E. C. (2020) · Pediatrics in Review · doi:10.1542/pir.2019-0134 · Cited by 122 · see citing works
The Pharmacological Basis of Cannabis Therapy for Epilepsy
Reddy, D. S., & Golub, V. M. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230151 · Cited by 121 · see citing works
Wirrell, E. C. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2016.249 · Cited by 115 · see citing works
Five‐year extended follow‐up status of 10 patients with Dravet syndrome treated with fenfluramine
Ceulemans, B., Schoonjans, A., Marchau, F., Paelinck, B. P., & Lagae, L. G. (2016) · Epilepsia · doi:10.1111/epi.13407 · Cited by 114 · see citing works
Self-citationA Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
Strzelczyk, A., & Schubert‐Bast, S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00898-1 · Cited by 114 · see citing works
Zhang, Y., Kecskés, A., Copmans, D., Langlois, M., Crawford, A. D., Ceulemans, B., Lagae, L. G., de Witte, P. A. M., & Esguerra, C. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125898 · Cited by 112 · see citing works
Self-citationBialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2017) · Epilepsia · doi:10.1111/epi.13634 · Cited by 110 · see citing works
Seizing the moment: Zebrafish epilepsy models.
Gawel, K., Langlois, M., Martins, T., van der Ent, W., Tiraboschi, E., Jacmin, M., Crawford, A., & Esguerra, C. (2020) · Neuroscience and Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.010 · Cited by 97 · see citing works
Stiripentol in D ravet syndrome: Results of a retrospective U . S . study
Wirrell, E. C., Laux, L., Franz, D. N., Sullivan, J. E., Saneto, R. P., Morse, R. P., Devinsky, O., Chugani, H. T., Hernandez, A. W., Hamiwka, L. D., et al. (2013) · Epilepsia · doi:10.1111/epi.12303 · Cited by 109 · see citing works
Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies
Guerrini, R., Balestrini, S., Wirrell, E. C., & Walker, M. C. (2021) · Neurology · doi:10.1212/wnl.0000000000012744 · Cited by 108 · see citing works
Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model
Sourbron, J., Schneider, H., Kecskés, A., Liu, Y., Buening, E., Lagae, L. G., Smolders, I. J., & de Witte, P. A. M. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00342 · Cited by 108 · see citing works
Self-citationDravet syndrome: Treatment options and management of prolonged seizures
Cross, J. H., Caraballo, R. H., Nabbout, R., Vigevano, F., Guerrini, R., & Lagae, L. G. (2019) · Epilepsia · doi:10.1111/epi.16334 · Cited by 108 · see citing works
Self-citationSchoonjans, A., Paelinck, B. P., Marchau, F., Gunning, B. W., Gammaitoni, A. R., Galer, B. S., Lagae, L. G., & Ceulemans, B. (2016) · European Journal of Neurology · doi:10.1111/ene.13195 · Cited by 104 · see citing works
Self-citationPreclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
Griffin, A., Hamling, K. R., Hong, S., Anvar, M., Lee, L. P., & Baraban, S. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00573 · Cited by 103 · see citing works
Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders
Golub, V. M., & Reddy, D. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_7 · Cited by 98 · see citing works
Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe
Cardenal‐Muñoz, E., Auvin, S., Villanueva, V., Cross, J. H., Zuberi, S. M., Lagae, L. G., & Aibar, J. Á. (2021) · Epilepsia Open · doi:10.1002/epi4.12569 · Cited by 95 · see citing works
Self-citationSerotonin and sudden unexpected death in epilepsy
Petrucci, A. N., Joyal, K. G., Purnell, B. S., & Buchanan, G. F. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113145 · Cited by 93 · see citing works
Recent Advances in the Drug Treatment of Dravet Syndrome
Wirrell, E. C., & Nabbout, R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00666-8 · Cited by 88 · see citing works
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., Merlos, M., & Garzón-Niño, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10095 · Cited by 87 · see citing works
Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome
Cross, J. H., Galer, B. S., Gil‐Nagel, A., Devinsky, O., Ceulemans, B., Lagae, L. G., Schoonjans, A., Donner, E. J., Wirrell, E. C., Kothare, S. V., et al. (2021) · Seizure · doi:10.1016/j.seizure.2021.10.024 · Cited by 87 · see citing works
Self-citationLow-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome
Schoonjans, A., Lagae, L. G., & Ceulemans, B. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615607726 · Cited by 85 · see citing works
Self-citationZebrafish as Toxicological model for screening and recapitulate human diseases
Caballero, M. V., & Candiracci, M. (2018) · Journal of Unexplored Medical Data · doi:10.20517/2572-8180.2017.15 · Cited by 90 · see citing works
Reddy, D. S. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114237 · Cited by 100 · see citing works
Pharmacotherapy for Dravet Syndrome
Wallace, A. D., Wirrell, E. C., & Kenney‐Jung, D. L. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0171-7 · Cited by 79 · see citing works
The pharmacological management of Lennox-Gastaut syndrome and critical literature review
Verrottı, A., Striano, P., Iapadre, G., Zagaroli, L., Bonanni, P., Coppola, G., Elia, M., Mecarelli, O., Franzonı, E., Liso, P. D., et al. (2018) · Seizure · doi:10.1016/j.seizure.2018.10.016 · Cited by 79 · see citing works
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Higgins, G. A., Fletcher, P. J., & Shanahan, W. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107417 · Cited by 79 · see citing works
New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndrome
Tiraboschi, E., Martina, S., van der Ent, W., Grzyb, K., Gaweł, K., Cordero-Maldonado, M. L., Poovathingal, S. K., Heintz, S., Satheesh, S. V., Brattespe, J., et al. (2020) · Epilepsia · doi:10.1111/epi.16456 · Cited by 74 · see citing works
Precision medicine in genetic epilepsies: break of dawn?
Reif, P., Tsai, M.-H., Helbig, I., Rosenow, F., & Klein, K. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1253476 · Cited by 67 · see citing works
Lagae, L. G., Schoonjans, A., Gammaitoni, A. R., Galer, B. S., & Ceulemans, B. (2018) · Epilepsia · doi:10.1111/epi.14540 · Cited by 71 · see citing works
Self-citationSullivan, J. E., Scheffer, I. E., Lagae, L. G., Nabbout, R., Pringsheim, M., Talwar, D., Polster, T., Galer, B. S., Lock, M. D., Agarwal, A., et al. (2020) · Epilepsia · doi:10.1111/epi.16722 · Cited by 69 · see citing works
Self-citationAdemuwagun, I. A., Rotimi, S. O., Syrbe, S., Ajamma, Y. U., & Adebiyi, E. F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.600050 · Cited by 68 · see citing works
Preventing cognitive impairment in children with epilepsy
Braun, K. P. J. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000424 · Cited by 67 · see citing works
Lamotrigine can be beneficial in patients with Dravet syndrome
Dalic, L., Mullen, S. A., Roulet Perez, E., & Scheffer, I. (2015) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12593 · Cited by 64 · see citing works
Boyd, B., Smith, S. M., Gammaitoni, A. R., Galer, B. S., & Farfel, G. M. (2018) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203276 · Cited by 64 · see citing works
Eimon, P. M., Ghannad‐Rezaie, M., Rienzo, G. D., Allalou, A., Wu, Y., Gao, M., Roy, A., Skolnick, J., & Yanik, M. F. (2018) · Nature Communications · doi:10.1038/s41467-017-02404-4 · Cited by 65 · see citing works
Therapeutic advances in Dravet syndrome: a targeted literature review
Strzelczyk, A., & Schubert‐Bast, S. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1801423 · Cited by 61 · see citing works
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know
Odi, R., Invernizzi, R. W., Gallily, T., Bialer, M., & Perucca, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107866 · Cited by 60 · see citing works
Patients with dravet syndrome in the era of stiripentol: A French cohort cross-sectional study
Liso, P. D., Chémaly, N., Laschet, J. J., Barnérias, C., Hully, M., Leunen, D., Desguerre, I., Chiron, C., Dulac, O., & Nabbout, R. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.05.012 · Cited by 59 · see citing works
Tupal, S., & Faingold, C. L. (2019) · Epilepsia · doi:10.1111/epi.14658 · Cited by 58 · see citing works
Lorcaserin therapy for severe epilepsy of childhood onset
Tolete, P., Knupp, K. G., Karlovich, M. W., DeCarlo, E., Bluvstein, J., Conway, E., Friedman, D. J., Dugan, P. C., & Devinsky, O. (2018) · Neurology · doi:10.1212/wnl.0000000000006432 · Cited by 57 · see citing works
Specchio, N., Pietrafusa, N., Doccini, V., Trivisano, M., Darra, F., Ragona, F., Cossu, A., Spolverato, S., Battaglia, D., Quintiliani, M., et al. (2020) · Epilepsia · doi:10.1111/epi.16690 · Cited by 56 · see citing works
Why we urgently need improved seizure and epilepsy therapies for children and neonates
Pressler, R., & Lagae, L. G. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107854 · Cited by 56 · see citing works
Self-citationEfficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes
Shi, X., Tomonoh, Y., Wang, W., Ishii, A., Higurashi, N., Kurahashi, H., Kaneko, S., & Hirose, S. (2015) · Brain and Development · doi:10.1016/j.braindev.2015.06.008 · Cited by 56 · see citing works
The challenges and innovations for therapy in children with epilepsy
Wilmshurst, J. M., Berg, A. T., Lagae, L. G., Newton, C. R. J. C., & Cross, J. H. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.58 · Cited by 55 · see citing works
Self-citationDravet syndrome: Advances in etiology, clinical presentation, and treatment
He, Z., Li, Y., Zhao, X., & Li, B. (2022) · Epilepsy Research · doi:10.1016/j.eplepsyres.2022.107041 · Cited by 57 · see citing works
From next-generation sequencing to targeted treatment of non-acquired epilepsies
Møller, R. S., Hammer, T. B., Rubboli, G., Lemke, J. R., & Johannesen, K. M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1573144 · Cited by 54 · see citing works
Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome
Griffin, A., Jaishankar, P., Grandjean, J.-M. M., Olson, S. H., Renslo, A. R., & Baraban, S. C. (2019) · Brain Communications · doi:10.1093/braincomms/fcz008 · Cited by 53 · see citing works
Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Badria, F. A.-E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83082 · Cited by 53 · see citing works
Sullivan, J. E., Lagae, L. G., Cross, J. H., Devinsky, O., Guerrini, R., Knupp, K. G., Laux, L., Nikanorova, M., Polster, T., Talwar, D., et al. (2023) · Epilepsia · doi:10.1111/epi.17737 · Cited by 52 · see citing works
Self-citationLagae, L. G. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000902 · Cited by 52 · see citing works
Self-citationPersonalized medicine in genetic epilepsies – possibilities, challenges, and new frontiers
Helbig, I., & Ellis, C. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107970 · Cited by 51 · see citing works
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., & Garzón, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25169 · Cited by 49 · see citing works
Lai, W. W., Galer, B. S., Wong, P. C., Farfel, G. M., Pringsheim, M., Keane, M. G., & Agarwal, A. (2020) · Epilepsia · doi:10.1111/epi.16638 · Cited by 48 · see citing works
Landmark, C. J., Potschka, H., Auvin, S., Wilmshurst, J. M., Johannessen, S. I., Trenité, D. G. A. K.-N., & Wirrell, E. C. (2021) · Epilepsia · doi:10.1111/epi.16849 · Cited by 48 · see citing works
Schoonjans, A., Marchau, F., Paelinck, B. P., Lagae, L. G., Gammaitoni, A. R., Pringsheim, M., Keane, M. G., & Ceulemans, B. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1355781 · Cited by 46 · see citing works
Self-citationEpilepsy: key experimental therapeutics in early clinical development
Steriade, C., French, J. A., & Devinsky, O. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1743678 · Cited by 45 · see citing works
Galanopoulou, A. S., Löscher, W., Lubbers, L. S., O'Brien, T. J., Staley, K. J., Vezzani, A., D’Ambrosio, R., White, H. S., Sontheimer, H. W., Wolf, J. A., et al. (2021) · Epilepsia Open · doi:10.1002/epi4.12490 · Cited by 45 · see citing works
Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy
Samanta, D. (2022) · Children · doi:10.3390/children9081159 · Cited by 45 · see citing works
SCN1B ‐linked early infantile developmental and epileptic encephalopathy
Aeby, A., Sculier, C., Bouza, A. A., Askar, B., Lederer, D., Schoonjans, A., Ghinst, M. V., Ceulemans, B., Offord, J., Lopez‐Santiago, L. F., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50921 · Cited by 44 · see citing works
Self-citationPernici, C. D., Mensah, J. A., Dahle, E. J., Johnson, K. J., Handy, L. J., Buxton, L., Smith, M. D., West, P. J., Metcalf, C. S., & Wilcox, K. S. (2021) · Epilepsia · doi:10.1111/epi.16925 · Cited by 44 · see citing works
Audit of use of stiripentol in adults with Dravet syndrome
Balestrini, S., & Sisodiya, S. M. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12611 · Cited by 43 · see citing works
Changing Landscape of Dravet Syndrome Management: An Overview
Samanta, D. (2020) · Neuropediatrics · doi:10.1055/s-0040-1701694 · Cited by 41 · see citing works
Strzelczyk, A., Pringsheim, M., Mayer, T., Polster, T., Klotz, K. A., Muhle, H., Alber, M., Trollmann, R., Spors, H., Kluger, G. J., et al. (2021) · Epilepsia · doi:10.1111/epi.17034 · Cited by 41 · see citing works
Advancing the management of childhood epilepsies
Cross, J. H., Kluger, G. J., & Lagae, L. G. (2013) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2013.02.003 · Cited by 40 · see citing works
Self-citationPolster, T. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.021 · Cited by 40 · see citing works
Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome
Balagura, G., Cacciatore, M., Grasso, E. A., Striano, P., & Verrottı, A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00755-z · Cited by 40 · see citing works
Auvin, S., Galanopoulou, A. S., Moshé, S. L., Potschka, H., Rocha, L., Walker, M. C., & the TASK1 workgroup on drug‐resistant epilepsy of the ILAE/AES Joint Translational Task Force (2023) · Epilepsia · doi:10.1111/epi.17751 · Cited by 39 · see citing works
Petrucci, A. N., Joyal, K. G., Chou, J. W., Li, R., Vencer, K. M., & Buchanan, G. F. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.029 · Cited by 38 · see citing works
Advances in the Treatment of Drug-Resistant Pediatric Epilepsy
Gonzalez‐Giraldo, E., & Sullivan, J. E. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1702941 · Cited by 35 · see citing works
Evaluation of Selective 5-HT 2C Agonists in Acute Seizure Models
Silenieks, L. B., Carroll, N. K., Niekerk, A. V., Niekerk, E. V., Taylor, C., Upton, N., & Higgins, G. A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00739 · Cited by 34 · see citing works
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials
Pong, A. W., Ross, J. D. C., Tyrlíková, I., Giermek, A. J., Kohli, M. P., Khan, Y. A., Salgado, R. D., & Klein, P. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2059464 · Cited by 34 · see citing works
Zaccara, G., & Schmidt, D. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.011 · Cited by 33 · see citing works
Investigating Developmental and Epileptic Encephalopathy Using Drosophila melanogaster
Takai, A., Yamaguchi, M., Yoshida, H., & Chiyonobu, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176442 · Cited by 33 · see citing works
Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight
Klein, P., Friedman, D. J., & Kwan, P. (2024) · CNS Drugs · doi:10.1007/s40263-024-01130-y · Cited by 32 · see citing works
Current Treatment Strategies and Future Treatment Options for Dravet Syndrome
Ziobro, J. M., Eschbach, K. L., Sullivan, J. E., & Knupp, K. G. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0537-y · Cited by 32 · see citing works
Serotonergic therapy in epilepsy
Gilliam, F. G., Hečimović, H., & Gentry, M. S. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000901 · Cited by 32 · see citing works
Fenfluramine as antiseizure medication for epilepsy
Γώγου, Μ., & Cross, J. H. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14822 · Cited by 31 · see citing works
Impact of Antiseizure Medications on Appetite and Weight in Children
Buraniqi, E., Dabaja, H., & Wirrell, E. C. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00505-2 · Cited by 32 · see citing works
Infantile, Childhood, and Adolescent Epilepsies
Wirrell, E. C. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000269 · Cited by 31 · see citing works
Assessing the role of serotonergic receptors in cannabidiol's anticonvulsant efficacy
Pelz, M. C., Schoolcraft, K. D., Larson, C. S., Spring, M. G., & López, H. H. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.04.045 · Cited by 31 · see citing works
Zebrafish Models of Epilepsy and Epileptic Seizures
Copmans, D., Siekierska, A., & de Witte, P. A. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00026-2 · Cited by 31 · see citing works
Vavers, E., Zvejniece, L., & Dambrova, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106771 · Cited by 30 · see citing works
Sills, G. J. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231191000 · Cited by 30 · see citing works
Dwivedi, R., Kaushik, M., Tripathi, M., Dada, R., & Tiwari, P. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149120 · Cited by 30 · see citing works
Cardiac adverse effects of antiseizure medications
Zaccara, G., Lattanzi, S., & Brigo, F. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2023128 · Cited by 30 · see citing works
Jensen, M. P., Gammaitoni, A. R., Galer, B. S., Salem, R., Wilkie, D., & Amtmann, D. (2022) · Epilepsy Research · doi:10.1016/j.eplepsyres.2022.106976 · Cited by 29 · see citing works
- Authors
- Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P. G., & Lagae, L.
- Affiliations
- University of Antwerp (BE)
- KU Leuven (BE)
- Corresponding author
- Ceulemans, Berten
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2012-05-03
- Volume
- 53
- Issue
- 7
- Pages
- 1131-1139
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1926532831
- Cited by
- 210
- References
- 51
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 18 · 2023: 13 · 2022: 20 · 2021: 28 · 2020: 27 · 2019: 23 · 2018: 18 · 2017: 13 · 2016: 15 · 2015: 8 · 2014: 5 · 2013: 3 · 2012: 1
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Epilepsia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology › Diet and metabolism studies
- Keywords
- Dravet syndrome, fenfluramine, adjunctive therapy, seizure freedom, drug repurposing, amphetamine-type stimulants, pulmonary hypertension, drug withdrawal, seizure recurrence, long-term follow-up
- MeSH terms
- Adolescent, Adult, Anticonvulsants, Child, Preschool, Electroencephalography, Epilepsies, Myoclonic, Female, Fenfluramine, Follow-Up Studies, Humans, Male, Selective Serotonin Reuptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
